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DOI 10.1016/j.ccr.2010.05.026SUMMARYAnnotation of prostate cancer genomes provides a foundation for discoveries that can impact disease under-
standing and treatment. Concordant assessment of DNA copy number, mRNA expression, and focused exon
resequencing in 218 prostate cancer tumors identified the nuclear receptor coactivator NCOA2 as an onco-
gene in 11% of tumors. Additionally, the androgen-driven TMPRSS2-ERG fusion was associated with
a previously unrecognized, prostate-specific deletion at chromosome 3p14 that implicates FOXP1, RYBP,
and SHQ1 as potential cooperative tumor suppressors. DNA copy-number data from primary tumors
revealed that copy-number alterations robustly define clusters of low- and high-risk disease beyond that
achieved by Gleason score. The genomic and clinical outcome data from these patients are nowmade avail-
able as a public resource.INTRODUCTION
Prostate cancer is the most common malignancy in males with
190,000 new cases diagnosed per year in the United States
and 27,000 deaths. Prostate tumors show tremendous biolog-
ical heterogeneity, with some patients dying of metastatic
disease within 2–3 years of diagnosis whereas others can live
for 10–20 years with organ-confined disease, likely a reflection
of underlying genomic diversity. Large-scale cancer genome
characterization projects studying glioblastoma, lung, colon,
pancreas, and breast cancers have provided critical new insightsSignificance
Current knowledge of prostate cancer genomes is largely bas
We present an integrated oncogenomic analysis of 218 primary
xenografts. Mutations in known, commonly mutated oncoge
BRAF, and TP53 are present but rare. However, integrative ana
changes revealed changes in the PI3K, RAS/RAF, and androgen
a high frequency of primary samples. These data clarify the role
cate several new ones, and provide a blueprint for clinical devinto the molecular classification of cancers and have the poten-
tial to identify new therapeutic targets (Cancer Genome Atlas
Research Network, 2008; Ding et al., 2008; Jones et al., 2008;
Parsons et al., 2008; Sjoblom et al., 2006; Weir et al., 2007;
Wood et al., 2007). Prostate cancer presents special challenges
for such large-scale multicenter genomics projects because of
the relatively small tumor size and admixture with stroma that
requires careful pathologist-guided dissection.
A number of groups have reported analyses of transcriptomes
and copy-number alterations (CNAs) in prostate cancer,
but rarely from the same samples and typically from modested on small patient cohorts using single modality platforms.
and metastatic prostate cancers as well as 12 cell lines and
nes and tumor suppressor genes such as PIK3CA, KRAS,
lysis of mutations, copy-number alterations, and expression
receptor (AR) pathways in nearly all metastatic samples and
of several known cancer pathways in prostate cancer, impli-
elopment of pathway inhibitors.
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Table 1. Summary of Clinical Characteristics for the Study
Cohort




Standard deviation 7 8.6
Min-max 37.3-83 41-82
PSA at Diagnosis (ng/ml)
Median 6 (IQR 4.4, 9) 17 (IQR 8.6, 46.6)
<4 31 (17.2%) 4 (12.5%)
4–10 105 (58.3%) 6 (18.75%)
>10 44 (24.5%) 22 (68.75%)
Initial Biopsy Gleason Score
5 2 (1%) –
6 101 (56%) 2 (6%)
7 61 (34%) 16 (46%)
8 11 (6%) 8 (23%)
9 6 (3%) 9 (25%)
Initial Clinical Stage
cT1c 95 (52.4%) 8 (22%)
cT2 76 (42%) 12 (33%)
cT3 9 (5%) 3 (8%)
cT4 – 1 (3%)
Not available – 9 (25%)
Ethnicity
Black 29 (16.1%) 2 (5.6%)
Asian 4 (2.2%) 0 (0%)
White Hispanic 0 (0%) 2 (5.6%)
White non-Hispanic 142 (78.5%) 32 (88.9%)
Unknown 6 (3.3%) 0 (0%)
The cohort is composed of
a primary tumors (n = 181; one patient with metastasis and primary
analyzed) and
b metastases (n = 37; one patient with two metastases analyzed), cell
lines (n = 7; CWR22RV1, DU145, PC3, VCaP, LNCaP, LNCaP104R,
LNCaP104S), and xenografts (n = 5; LAPC9, LNM971, LuCaP35,
LAPC3, and LAPC4 [for both, two samples at different passages]). See
also Figure S1 and Table S1.
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platforms (Kim et al., 2007; Lapointe et al., 2004, 2007; Lieber-
farb et al., 2003; Perner et al., 2006; Singh et al., 2002). Con-
sistent and common findings from these reports include the
TMPRSS2-ERG fusion in 50%, 8p loss in 30%–50%, and
8q gain in 20%–40% of cases. The data implicating ERG as
a prostate cancer gene are clear (Tomlins et al., 2005), but there
has been less progress in defining specific genes targeted by
various common amplifications and deletions, in part due to
limited availability of complementary transcriptome and exon
resequencing data on sufficient patients to narrow the focus to
a small list of candidate genes. Numerous transcriptome studies
have defined general prostate cancer signatures, but, unlike
breast cancer (Paik et al., 2004; van de Vijver et al., 2002), these
analyses have not identified robust subtypes of prostate cancer
with different prognoses (Febbo and Sellers, 2003; Lapointe
et al., 2004; Singh et al., 2002).
Here, we adopted a comprehensive approach to define tran-
scriptomes and CNAs in 218 prostate tumors (181 primaries,
37 metastases) and 12 prostate cancer cell lines and xenografts,
as well as complete exon resequencing and/or focused mutation
detection for 157 high interest genes in 80 tumors and 11 cell/
xenograft lines (Table 1). After generating a map of CNAs across
the data set, we used matching mRNA and microRNA transcrip-
tome and exon resequencing data to define the frequency of
alterations in several common signal transduction pathways,
explore various candidate genes within a few selected regions
of copy-number gain and loss, and correlate genomic alter-
ations to clinical outcome. These data serve as a valuable
resource for the cancer genomics community, prostate cancer
scientists and clinicians and is readily and freely available
through a user-friendly web-based portal (http://cbio.mskcc.
org/prostate-portal/).
RESULTS
Global Copy-Number and Transcriptome Profiles Define
Core Pathway Alterations
We applied rigorous criteria for selecting tumors for genomic
analysis that have become the standard in large genomic studies
(Cancer Genome Atlas Research Network, 2008) but adapted to
address unique challenges posed by prostate cancers. All 218
samples had at least 70% tumor content (Table 1; Figure S1
and Table S1 available online). Transcriptome (mRNA and micro-
RNA) and CNA profiling were conducted without amplification,
with the exception of exon resequencing, which required
whole-genome amplification. Because we did not impose
a stringent tumor size requirement, the small size of some tumors
precluded concurrent analysis across all four platforms (Table 2;
Table S2).
Analysis of known prostate cancer alterations in our data set
indicates successful tumor selection criteria (Figure S1). For
example, the frequency of ERG alteration was 52% (see Exper-
imental Procedures), consistent with other studies, and chromo-
some 8p loss and 8q gain were easily detected (Figure 1A). Overt
CNAs were observed in 89% of tumors, also indicative of high
tumor content. Additional histologic and molecular analysis of
those tumors without CNA confirmed high tumor content (e.g.,
detection of TMPRSS2-ERG translocations). To address the12 Cancer Cell 18, 11–22, July 13, 2010 ª2010 Elsevier Inc.possibility that our stringent tumor selection criteria might bias
our data set toward larger, more aggressive prostate cancers,
we compared the clinical outcome of the 181 primary tumors
(Table S1) in this data set with 3437 consecutive men with pros-
tate cancer treated by prostatectomy at MSKCC from 2000 to
2006. The time to biochemical relapse, defined as an increase
in serum prostate-specific antigen, was somewhat shorter in
this study cohort (Table 1; Figure S1A). While this indicates
that genomic findings from these samples may be biased toward
larger, more aggressive prostate cancers (selected to ensure
sufficient nucleic acid yield), this cohort nevertheless includes
patients with favorable long-term clinical outcome (24% of
patients have >5 years of recurrence-free survival).
Global analysis of CNA data from 194 tumors and 12 cell
lines/xenografts revealed broad diversity in alteration levels.
Table 2. Number of Primary and Metastatic Tumors Analyzed by
Each Platform
Data Type Primariesa Metastases
Cell Lines/
Xenografts All
aCGH 157 37 13 207
mRNA 131 (29) 19 6 156
miRNA 99 (28) 14 0 113
Sequencingb 75 5 11 98
aCGH, mRNAc 109 19 5 133
aCGH, mRNA, miRNAc 79 13 2 94
aCGH, miRNA,
sequencingb,c
72 2 0 74
aCGH, mRNA, miRNA,
sequencingb,c
61 1 0 62
Summary of tumors and characterization platforms:
a number of samples in parentheses refers to the count of matching
normal prostate expression;
b sequencing category includes only tumors with matched normals and
cell/xenografts lines; and
c mRNA and miRNA refers to expression profiling data. See also
Tables S2 and S5.
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number of whole chromosome, chromosome arm, and focal
amplifications and deletions, but primary tumors also displayed
a wide range of alteration levels, from tumors appearing meta-
static-like in profile to those with fundamentally diploid genomes
(Figure S1B). Regions of recurrent CNA were identified using the
statistical method RAE (Taylor et al., 2008), revealing 30 focal
amplifications and 36 focal deletions as well as recurrent gains
and losses of seven chromosome arms (Figure 1A; Tables S3
and S4). The most frequent alteration in the prostate oncoge-
nome was loss of chromosome 8p, a common abnormality in
many epithelial tumors that harbors NKX3.1 (He et al., 1997).
Interestingly, NKX3.1 mRNA expression did not correlate with
copy-number loss, suggesting the possibility of alternative tumor
suppressors in this region. Consistent with prior studies, we also
found peaks of deletion targeting PTEN on 10q23.31, RB1 on
13q14.2, TP53 on 17p31.1, and the interstitial 21q22.2-3 deletion
spanning ERG and TMPRSS2. Other broader deletions included
12p13.31-p12.3, which spans ETV6 and DUSP16 in addition to
CDKN1B, the previously reported target of this genomic deletion
(Lapointe et al., 2007). The most common amplified loci included
MYC on 8q24.21 and a previously unreported NCOA2 amplifica-
tion on 8q13.3 (discussed further below). Focal amplifications of
AR (Xq12) were also common but restricted to metastatic
tumors. Other gains span discontinuous regions of 7q, including
genes such as BRAF and EZH2, for which we were unable to
localize individual target genes. We observed less frequent gains
of 5p13.3-p13.1 spanning AMACR, RICTOR, and SKP2 as well
as 47 other genes and two microRNAs.
Eighty tumors were examined for somatic mutations in 138
genes by exon sequencing (Figure 1A; Tables S5 and S6). These
and an additional 76 tumors were also profiled for well-known
oncogenic mutations in 22 genes by mass spectrometry using
the iPLEX Sequenom assay (Table S5). In total, 84 confirmed
somatic mutations were detected in 57 different genes(Table S6). Thirty-seven percent of the missense mutations we
detected are predicted to affect protein function (Table S6)
based on an algorithm that uses a combination of evolutionary
information from protein-family sequence alignments and
residue placement in known or homology-deduced three-
dimensional protein and complex structures (B.R., Y.A., C.S.,
unpublished data; http://www.mutationassessor.org/). Among
all mutated genes, including those bearing previously known
mutations, the most commonly mutated gene was the androgen
receptor (AR), with four samples, all metastases. Mutations in 21
other genes were detected in two or more samples, but no single
gene other than AR had mutations in more than three samples.
We also confirmed prior data suggesting that common, broadly
mutated oncogenes such as PIK3CA, KRAS, and BRAF are
not commonly mutated in prostate cancer (two tumors had
H1047R and E545K PIK3CA mutations, two had G12V and
Q61H/L KRAS mutations, and one tumor had a BRAF V600E
mutation). Mutations in other more recently identified oncogenes
such as IDH1 and IDH2 were similarly rare, with only one tumor
bearing an IDH2 R172K mutation. Curiously, one tumor with
a mutation in the mismatch repair gene MSH6 (V250A) had 11
confirmed somatic mutations versus an average of two somatic
mutations per tumor, suggestive of a mutator phenotype.
Mutations in two other DNA repair genes, BLM and XPC, were
each found in a single tumor, but not in association with an
increased number of other mutations. Only two tumors had
missense mutations in TP53 and none had mutations in PTEN,
but both tumor suppressors were commonly altered through
hetero- or homozygous copy-number loss (24% and 21%,
respectively). Comparison of synonymous and nonsynonymous
changes detected in these samples suggests a low mutation rate
in prostate cancer (0.31 mutations/Mb). Consistent with this
notion, the frequency of mutations recovered in our analysis
did not exceed the expected background rate (Ding et al.,
2008), although the modest number of genes and samples
sequenced limits this analysis.
We next integrated the CNA, transcriptome, and mutation data
to conduct a core pathway analysis, based on the success of
this approach in revealing common pathway alterations in glio-
blastoma (Cancer Genome Atlas Research Network, 2008).
Three well-known cancer pathways were commonly altered,
PI3K, RAS/RAF, and RB, with frequencies ranging from 34% to
43% in primary tumors versus 74% to 100% in metastases
(Figure 1B). In this analysis, a tumor was considered altered if
one or more genes in the pathway were mutated or significantly
deregulated at the expression level (outlier expression compared
to the distribution of expression in normal prostate samples, see
Experimental Procedures). As in glioblastoma, the extremely
high frequency of alteration in these pathways became evident
only through examination of multiple genes in each pathway
since individual genes are affected less commonly. Of particular
interest is the PI3K pathway, which was altered in nearly half of
primaries and all metastases examined. Loss of PTEN function,
through deletion, mutation, or reduced expression, has been
well documented in prostate cancer with an estimated frequency
of 40% (Pourmand et al., 2007), consistent with our findings
here. The frequency of PI3K pathway alteration rises substan-
tially when PTEN alterations are considered together with alter-




Figure 1. A Global View of the Prostate Cancer Genome
(A) Significant genomic aberrations in the prostate oncogenome. Regions of amplification (red) or deletion (blue) with FDR%10% are plotted, with chromosomes
indicated at the center and centromeres in red. Genes in which we detected somatic nonsynonymous mutations are listed on top (black). Additional genes of
interest targeted by copy-number alterations alone are also indicated (gray).
(B) Three of the most commonly altered pathways in both primary and metastatic prostate cancers: RB, PI3K, and RAS/RAF signaling. Alteration frequencies are
shown for individual genes and for the entire pathway in primary and metastatic tumors. Alterations are defined as those having outlier expression (significant up-
or downregulation) compared with the distribution of expression in normal prostate samples (outlier analysis described in further detail in Experimental Proce-
dures), or by somatic mutations, and are interpreted as activation (red) or inactivation (blue) of protein function. See also Figure S1 and Tables S3 and S6.
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PIK3CA regulatory subunits PIK3R1 and PIK3R3 (Cancer
Genome Atlas Research Network, 2008; Gao et al., 2005; Gewin-
ner et al., 2009; Jaiswal et al., 2009; Ueki et al., 2003). These data
provide strong rationale for exploring the clinical activity of PI3K
pathway inhibitors, many of which are now in early clinical devel-
opment, in prostate cancer.14 Cancer Cell 18, 11–22, July 13, 2010 ª2010 Elsevier Inc.Common Genomic Alterations in Androgen Receptor
Signaling Pathway Members
We also conducted a core pathway analysis of AR, which is
essential for growth and differentiation of the normal prostate
and is responsible for treatment failure in castration-resistant,
metastatic disease (Chen et al., 2004; Tran et al., 2009). As






Figure 2. Diversity of Androgen Signaling Pathway Alterations in Primary and Metastatic Prostate Cancers
(A) Alterations in androgen signaling components where frequencies are shown for AR and selected modulators in primary and metastatic tumors. Alterations are
defined as those having outlier expression (as described in Figure 1B and Experimental Procedures), or by somatic mutations, and interpreted as activation (red)
or inactivation (blue).
(B) Overall genomic alteration rates in androgen signaling genes. The 11 genes in the AR pathway (A) had somatic mutations (black, red) and/or outlier expression
(over- or underexpression, see Experimental Procedures), a subset of which was the result of copy-number alterations (gray, broad and focal gain or loss of one or
more copies, see the Supplemental Information). Primary tumors show moderate levels of alteration in at least one of these 11 AR pathway genes (left), preceding
the generally higher alteration rates in metastatic tumors (right).
(C) The steroid receptor coactivator NCOA2 had two novel somatic point mutations in primary tumors. These clustered near sites of known NCOA2 point muta-
tions in melanoma (G435S in the serine/threonine-rich [S/T] regulatory domain) and lung cancer (S1024N in the transcriptional activation domain 1 [AD1]).
(D) Increasing levels of NCOA2 induce increasing androgen-dependent AR transcriptional activity. Increasing amounts of NCOA2 plasmid were transfected into
LNCaP cells, resulting in NCOA2 protein expression (inset western blot) and ARE-luciferase reporter activity. Error bars representing the SEM (standard error of
the mean) are displayed but represent a very small portion of the signal and are therefore not visible.
(E) Noncastrate primary tumors withNCOA2 gain (defined as copy-number amplification greater than single-copy gain, outlier overexpression, or mutation) have
higher androgen signaling (Student’s t test, p < 0.0001), as assessed by an independent signature of 29 androgen-responsive genes (Hieronymus et al., 2006).
See also Figure S2.
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metastatic samples (58%, Figure 2A). However, AR pathway
analysis (including several known AR coactivators and corepres-
sors) revealed alteration in 56% of primaries and 100% in metas-
tases (Figure 2A; Figure S2). Among AR pathway genes, the most
striking finding was a peak of copy-number gain on 8q13.3
(57 Mb away from the peak at 8q24 commonly attributed to
MYC, and of even greater significance) that spans the nuclear
receptor coactivator gene NCOA2 (also known as SRC2/TIF2/
GRIP1). Seventeen percent of tumors had broad gains of the
region spanning NCOA2 on 8q, whereas 6.2% of tumors (1.9%
and 24.3% of primary and metastases, respectively) harbored
focal or high-level amplifications of the locus and these weresignificantly correlated with elevated NCOA2 transcript levels
(p < 1016, Figure S2A). In addition to copy-number and expres-
sion changes, AR pathway alterations included mutations in
NCOA2 (two confirmed somatic) as well as in NCOR2 (three
tumors), NRIP1, TNK2, and EP300 (one tumor each). Overall,
8% of primary tumors and 37% of metastases had NCOA2
gain of expression (determined to be outlier expression as
described in Experimental Procedures) or mutation (Figures 2A
and 2B). Including broader gains of 8q, the frequency of
NCOA2 alteration may be as high as 20% and 63% in primary
and metastatic tumors, respectively. Of note, NCOA2 mutations
have also been reported in melanoma and lung cancer and, in
conjunction with the prostate mutations detected here, clusterCancer Cell 18, 11–22, July 13, 2010 ª2010 Elsevier Inc. 15
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nine-rich stretch (S/T) known to be phosphorylated and an acti-
vation domain (AD1) that mediates binding with histone acetyl-
transferases such as CBP and p300 (Huang and Cheng, 2004)
(Figure 2C). A third patient had an A407S NCOA2 substitution
that was potentially germline (detected at low frequency in adja-
cent normal prostate). Interestingly, noncastrate patients with
primary tumors harboring NCOA2 mutation, overexpression, or
high-level amplification had significantly higher rates of recur-
rence (Figure S2B).
The combination of the high frequency of NCOA2 gain in
primary tumors and its known role as an AR coactivator (Agoulnik
et al., 2005) suggests that these two genes might collaborate in
early prostate cancer progression by enhancing AR transcrip-
tional output. We addressed this possibility by expressing
increasing levels of NCOA2 in prostate cancer cells with a fixed
endogenous level of nonamplified AR. The range in NCOA2
protein levels is shown by Western blot (Figure 2D) and is
similar to the 2- to 4-fold increase in NCOA2 mRNA levels
over the mean level seen in the overall prostate cancer cohort.
As expected from other work, AR transcriptional output (mea-
sured using an androgen-responsive reporter construct) was
increased when cells were treated with dihydrotestosterone
(DHT) in a dose-dependent fashion, but reached a plateau
between 1 and 10 mM (Figure 2D). Increasing levels of NCOA2
shifted the DHT dose-response curve leftward and upward, indi-
cating that NCOA2 can not only prime AR to respond to lower
androgen concentrations but can also boost the total magnitude
of AR transcriptional output. One prediction from these in vitro
data is that the AR transcriptional output in prostate cancers
with NCOA2 gene amplification should be greater than those
without. Based on a 29-gene signature of AR transcriptional
output previously used to conduct small molecule screens for
novel antiandrogens (Hieronymus et al., 2006), NCOA2-ampli-
fied primary tumors displayed an increase in AR signaling (Fig-
ure 2E). Collectively, the genomic and functional data suggest
that NCOA2 functions as a driver oncogene in primary tumors
by increasing AR signaling, which is known to play a critical
role in early and late stage prostate cancer. In contrast, AR
amplification, which is largely restricted to castration-resistant
metastatic disease, is more likely a mechanism of drug resis-
tance rather than a natural step in tumor progression. We also
propose that NCOA2 and MYC both function as driver onco-
genes on the 8q13 and 8q24 amplicons, respectively.
Genetic Alterations Highly Associated
with TMPRSS2-ERG
The TMPRSS2-ERG fusion is the single most prevalent molec-
ular lesion in prostate cancer (Tomlins et al., 2005). Functional
studies of TMPRSS2-ERG, including transgenic expression in
the mouse prostate, have shown modest evidence of oncogenic
activity (Carver et al., 2009; King et al., 2009; Klezovitch et al.,
2008; Tomlins et al., 2008), which raises the possibility that coop-
erating events are required.
Analysis of 194 tumors for CNAs associated with TMPRSS2-
ERG fusion revealed three significant regions of copy-number
loss: two spanning the tumor suppressors PTEN and TP53 and
a third spanning the multigenic region at 3p14 (Figure 3A).
PTEN loss was recently shown to cooperate with TMPRSS2-16 Cancer Cell 18, 11–22, July 13, 2010 ª2010 Elsevier Inc.ERG in transgenic mice and in a prostate tissue reconstitution
model (Carver et al., 2009; King et al., 2009; Zong et al., 2009).
The 3p14 deletion, whose association with TMPRSS2-ERG
was even more significant, has not been previously reported
and spans only eight genes. Further interrogation of 2550 tumors
and cell lines spanning 14 tumor types (acute lymphoid leu-
kemia, breast, colorectal, esophageal, glioma, hepatocellular,
non-small cell lung, squamous lung, medulloblastoma, mela-
noma, myeloproliferative, ovarian, renal, and prostate) for CNAs
in this region suggests this deletion is only found in prostate
cancer (Beroukhim et al., 2010). Indeed, the only other focal
signal found in this region is an amplicon in melanoma that
includes microphthalmia-associated transcription factor (MITF),
a previously reported finding (Garraway et al., 2005).
Closer inspection of the 3p14 deletion in our prostate cohort
revealed two distinct peaks of association within the region that,
together with expression data and the focal deletion patterns,
implicates only three genes: FOXP1, RYBP, and SHQ1 (Figures
3B and 3C). Deletions in some tumors spanned FOXP1 only,
whereas others included RYBP and SHQ1, but spared FOXP1.
FOXP1encodes a forkhead box transcription factor and functions
in motor neuron specification in the spinal cord, as well as early
thymocyte development, in collaboration with variousHOXgenes
(Arber, 2008; Pfaff, 2008). A role for FOXP1 in cancer has been
proposed based on reduced expression in breast and other
cancers, increased expression in some lymphoid malignancies
and, remarkably, by translocation-mediated fusion to the ERG
homolog ETV1 in at least one prostate cancer (Goatly et al.,
2008; Hermans et al., 2008; Koon et al., 2007). Furthermore,
recent evidence implicates the FoxP family member FOXP3 as
a potential tumor suppressor in prostate cancer (Wang et al.,
2009).RYBP (Ring and YY1 Binding Protein) encodes a polycomb
group transcriptional repressor implicated in homeotic develop-
ment and, potentially, as a tumor suppressor through inhibition
of MDM2 and subsequent p53 stabilization (Chen et al., 2009).
SHQ1 encodes an accessory factor for the assembly of H/ACA
ribonucleoproteins (RNP) through direct binding to NAP57,
a core RNP subunit. Missense mutations in NAP57 that disrupt
interaction with SHQ1 are associated with the bone marrow
failure syndrome dyskeratosis congenita, raising a potential link
to precancer syndromes (Grozdanov et al., 2009).
To gather further evidence for a potential tumor suppressor
role of either of these genes, we searched for point mutations
through exon resequencing. We found no mutations in FOXP1
or RYBP, but detected a confirmed somatic mutation in SHQ1
(P22S) in a highly conserved region of the CS domain that is
required for SHQ1 function (Singh et al., 2009). A second tumor
had a deletion targeting the middle of the SHQ1 gene that,
consequently, resulted in production of an aberrant mRNA
species truncated at exon 6 (Figure 3D). Although these data
further implicate SHQ1 as a tumor suppressor in this locus, the
fact that some tumors with 3p14 loss spare SHQ1 (Figure 3B) rai-
ses the possibility of multiple tumor suppressors in this region.
Unsupervised Clustering of CNAs Reveals Distinct
Subgroups with Differing Risk of Relapse
after Prostatectomy
Given the pressing need for biomarkers that distinguish indolent




Figure 3. TMPRSS2-ERG-Associated Deletion of 3p14.1-p13
(A) TMPRSS2-ERG gene fusion co-occurs with genomic aberrations in the prostate cancer genome including deletions of loci encoding TP53 (17p13.1) andPTEN
(10q23.31), as well as focal deletion of 3p14.1-p13 (genes listed in genomic order; green lines represent statistically significant associations, FDR%1%). Chro-
mosomes are shown around the ring.
(B) Diverse genomic deletions (heterozygous and homozygous deletions, light and dark blue, respectively) target a2.2 Mb region of 3p14.1-p13 encoding eight
genes (indicated at bottom). Tumors are rows and those harboring TMPRSS2-ERG fusion or PTEN/TP53 deletion (heterozygous and homozygous deletions are
black and gray, respectively) are identified at right. Tumors are sorted according to their locus of deletion with focal losses preferentially affecting FOXP1 (top),
RYBP and the adjacent gene SHQ1 (bottom), or both loci simultaneously (middle). Inset indicates the pattern of significance of total genomic deletion juxtaposed
to the significance of TMPRSS2-ERG-associated deletion (black and dotted blue, respectively).
(C) Transcript expression according to copy-number status for the three genes targeted by the 3p14.1-p13 deletion: FOXP1, RYBP, and SHQ1, all three of which
are correlated (p values as indicated, ANOVA). EIF4E3 and PPP4R2 expression and copy-number loss were also correlated, but neither of these two genes was
focally targeted by 3p14.1-p13 deletion.
(D) Along with whole-gene deletions of SHQ1 (B), we detected a single tumor with a P22S somatic mutation of the CS domain, indicated in red in the three-dimen-
sional structure of the SHQ1 yeast homolog (3eud) and in linear representation of the protein (top right). Also, intragenic deletions (shown here in metastatic
sample PCA0187) confer exon-specific loss of expression indicating a truncation event (bottom right).
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men diagnosed with prostate cancer could avoid surgery or radi-
ation (and instead be followed by watchful waiting) because they
have good-prognosis tumors that are unlikely to progress (Coop-
erberg et al., 2005). Whereas transcriptome analysis defines
breast cancer subgroups with distinct prognoses and treatment
outcomes that have changed clinical practice (Paik et al., 2004;
van de Vijver et al., 2002), similar studies in prostate cancer have
been less clinically useful (Mucci et al., 2008a, 2008b). The 5 year
median clinical follow-up linked to this tumor set provided an
opportunity to address the prognosis question using variousforms of oncogenomic data. While unsupervised hierarchical
clustering of mRNA and microRNA data failed to identify robust
clusters of patients with significant differences in prognosis, the
CNA data revealed distinct subgroups with substantial differ-
ences in time to biochemical (PSA) relapse (Figures 4A and 4B;
Figure S3A–S3C). Further attempts to identify individual genes
whose expression has prognostic impact through outlier anal-
ysis (1766 genes with over- or underexpressing outliers relative
to normal prostate) were only modestly successful and these
associations were weak relative to those observed using the
CNA data.Cancer Cell 18, 11–22, July 13, 2010 ª2010 Elsevier Inc. 17
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Figure 4. Genomic Aberrations Identify Clinically Distinct Subtypes of Prostate Cancer
(A) Unsupervised hierarchical clustering of copy-number alterations (heat map; red represents amplification, white represents copy-neutral, blue represents dele-
tion) indicates six groups of prostate cancers exist. Samples are ordered on the basis of their group membership (dendrogram, groups are colored; metastatic
samples are indicated by hashes). Selected genomic regions indicative of group membership are labeled (right).
(B) There exist significant differences in the risk of biochemical recurrence among the groups of tumors determined by patterns of genomic aberrations (left;
p values as indicated, log-rank test).
(C) Differences in the risk of biochemical relapse (B) were independent of Gleason grade (%6) in the most diploid clusters (1–4) (no statistically significant asso-
ciation of Gleason grade in clusters 1–4). See also Figure S3 and Table S4.
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tumors, those with minimal CNA (clusters 1–4) and those with
substantial CNA (clusters 5 and 6) that include most of the meta-
static samples (Figure 4A). Clusters 5 and 6 are distinguished by
the fact that cluster 5 tumors have genome-wide alterations,
whereas those in cluster 6 primarily have 8q (NCOA2, MYC) or
chromosome 7 gains. Among the tumors with minimal CNA,
cluster 2 is characterized by largely unaltered genomes. Using
the endpoint of time to biochemical relapse, primary tumors
with generally diploid tumors in the minimally altered cluster 2
had an extremely favorable prognosis versus an extremely
unfavorable prognosis for the highly altered cluster 5 tumors
(Figure 4B).18 Cancer Cell 18, 11–22, July 13, 2010 ª2010 Elsevier Inc.We next examined whether the prognostic impact of CNA is
simply a reflection of genomic instability or the impact of specific
genomic alterations. The fact that the two clusters with the highest
prevalence of CNAs (5 and 6) have statistically different outcomes
supports the latter hypothesis. To explore this question further, we
systematically examined the impact of gain or loss of whole chro-
mosome arms or more focal regions of gain or loss across the
genome. Combined loss of 13q and 18q, focal amplification of
two distinct 5p regions (5p13 or 5p15), and focal deletion of
5q21.1wereeachsignificantly associatedwith a negative outcome
(Figures S3B and S3C), further supporting the notion that distinct
genomic alterations impact prognosis and raising the possibility
that genes in these regions play functional roles in prostate cancer.
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Genomic Characterization of Human Prostate CancersThese findings raise the possibility that CNA assessment at
diagnosis may have clinical utility in distinguishing low- from
high-risk disease, but only if these data add to the prognostic
impact currently provided by the histology-based Gleason
score. Poor prognosis Gleason score (>7) tumors were distrib-
uted across clusters 2–6 (albeit with greatest frequency in
cluster 5), indicating that histology and CNA are not overlapping
(Figure 4C). Furthermore, low-risk Gleason scores (%6) were not
enriched among clusters 1–4. Therefore, Gleason grade cannot
fully explain the association with biochemical relapse. These
results raise the possibility of a CNA-based test that might guide
treatment choice in men with newly diagnosed prostate cancer,
though this would require validation in a larger independent data
set and confirmation that such information can be obtained from
biopsies rather than prostatectomy samples. Such a test might
be a genome-wide assessment using array-based CGH or
multiple inversion probe (MIP) technology (Wang et al., 2005)
or be centered on specific regions of gain or loss identified
through further confirmatory studies.
DISCUSSION
The clinical heterogeneity of prostate cancer, coupled with its
high prevalence, raises challenges in the management of newly
diagnosed patients as well as those with metastatic disease.
Genomic-based classification offers the hope of more informed
clinical decision-making and may yield novel therapeutic targets.
Integrated large-scale cancer genomics projects in several
tumor types have established the utility of this approach for
generating the data sets required to derive such classification
schema (Cancer Genome Atlas Research Network, 2008; Chitale
et al., 2009; Ding et al., 2008; Jones et al., 2008; Parsons et al.,
2008; Sjoblom et al., 2006; Weir et al., 2007; Wood et al.,
2007). These reports provide definitive overviews of the
genomes of those tumor types and in cases such as TCGA
provide easy, web-based access to genomic data that serves
as a public resource. The prostate cancer data set generated
here is comparable in size (218 carefully selected, well-anno-
tated tumors) and scope (transcriptome, CNA, exon resequenc-
ing) and is linked to clinical outcome. All raw and processed data
is freely accessible at http://cbio.mskcc.org/prostate-portal/.
One observation from the exon resequencing data is that
somatic point mutations in prostate cancer may be rare relative
to other tumor types such as glioblastoma, lung cancer and
melanoma (Greenman et al., 2007; Pleasance et al., 2010a;
Pleasance et al., 2010b). With the caveat that only 138 genes
were examined (selected primarily based on known roles in other
cancers), no single gene emerged as commonly mutated. TP53
and PTEN, which are often cited as prostate cancer tumor
suppressors (Dong, 2006; Pourmand et al., 2007), were com-
monly altered, but primarily through copy-number loss rather
than point mutation. Ongoing comprehensive sequencing
studies (whole-genome or whole-exome capture) will provide
more insight into the overall mutation rate in prostate cancer.
Several findings have emerged from our analysis, largely
based on the opportunity provided by integrated analysis
of multidimensional data. The nuclear receptor coactivator
NCOA2 was identified as a highly significant target gene on the
8q13 amplicon and is also subject to mutation in some tumorslacking gene amplification. Functional studies presented here
support the hypothesis that increased NCOA2 dosage amplifies
AR pathway transcriptional output in primary tumors, providing
a mechanism for its potential role as a prostate cancer onco-
gene. Whereas AR gene amplification or mutation is generally
restricted to metastatic, castration-resistant disease (acquired
in association with treatment resistance), CNAs or mutations in
NCOA2 and other regulators of nuclear receptor function such
as NCOR2 are present in primary tumors, thereby extending
the potential importance of AR pathway perturbation to disease
initiation.
A second finding is a narrow deletion on 3p14 highly associ-
ated with TMPRSS2-ERG fusion-positive tumors that appears
to be present only in prostate cancers. Integrative analysis of
copy-number, transcriptome, and exon resequencing data
implicates three genes within this region (FOXP1, RYBP, and
SHQ1) as potential context-specific tumor suppressors, either
alone or in combination. Our methodology also confirmed prior
reports of an association of TMPRSS2-ERG with PTEN loss
(Han et al., 2009; Reid et al., 2010), an interaction that has now
been validated by in vivo studies in mice (Carver et al., 2009;
King et al., 2009; Zong et al., 2009). We found evidence of
a possible association with 16q23 deletion previously reported
by others (Demichelis et al., 2009), but this did not reach statis-
tical significance in our larger data set. As has been done with
PTEN, these new associations warrant future functional studies
and could define unique ERG-specific tumor suppressor
interactions.
These findings together with our analysis showing the high
impact of CNA data on risk of relapse relative to transcriptome
profiling demonstrate the broad utility of this integrated prostate
oncogenome data set. The high prevalence of this important
disease and the relative paucity of large comprehensive genomic
data sets in prostate cancer make this a unique public resource
for the cancer research community.EXPERIMENTAL PROCEDURES
Specimen Collection and Annotation
A total of 218 tumor samples and 149 matched normal samples were obtained
from patients treated by radical prostatectomy at Memorial Sloan-Kettering
Cancer Center. All patients provided informed consent and samples were
procured and the study was conducted under Memorial Sloan-Kettering
Cancer Center Institutional Review Board approval. Clinical and pathologic
data were entered and maintained in our prospective prostate cancer data-
base. Following radical prostatectomy, patients were followed with history,
physical exam, and serum PSA testing every 3 months for the first year, 6
months for the second year, and annually thereafter. For all analyses described
here, biochemical recurrence (BCR) was defined as PSA R0.2 ng/ml on two
occasions. At the time of data analysis, patient follow-up was completed
through December 2008.Analyte Extraction and Microarray Hybridization
DNA and RNA were extracted from dissected tissue containing greater than
70% tumor cell content as well as from seven cell lines and seven xenografts
(see Supplemental Information). Resulting DNA and RNA were hybridized to
Agilent 244K array comparative genomic hybridization (aCGH) microarrays,
Affymetrix Human Exon 1.0 ST arrays, and/or Agilent microRNA V2 arrays,
respectively (Table 2). The normalization and statistical analysis of both DNA
copy-number and expression array data are available in the Supplemental
Information.Cancer Cell 18, 11–22, July 13, 2010 ª2010 Elsevier Inc. 19
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In total, 251 million bases in coding exons and adjacent intronic sequences of
138 cancer-related genes in 91 samples were PCR-amplified and sequenced
by Sanger capillary sequencing (Table S5). Ninety-five sites of known mutation
in 22 genes were also genotyped using the iPLEX Sequenom platform.
The details of whole-genome amplification, sequencing, mutation detection
pipelines, mutation validation, background mutation rate analysis, and Seque-
nom genotyping are described in the Supplemental Information.
Outlier Expression Analysis
Outlier profiles for all transcripts and outlier assignments in all tumors were
determined from normalized expression data as previously described (Ghosh
and Chinnaiyan, 2009). In brief, in this nonparametric approach an empirical
distribution function generated from transcript expression in the 29 normal
prostate tissues was used to transform expression in the tumor samples,
from which outliers were determined with the criteria described in the Benja-
mini and Hochberg algorithm (Benjamini and Hochberg, 1995) at an error
rate (a) = 0.01.
TMPRSS2-ERG Fusion Classification
For the purposes of the association analysis among copy-number alterations
(described in detail in the Supplemental Information), we classified fusion-
positive tumors exclusively from aCGH data to maximize our power to detect
novel associations in CNA data alone. Tumors were considered fusion-positive
if they harbored canonical 21q22.2-3 genomic deletion (D0 or D1 > 0.9 from
RAE analysis) with 50 and 30 breakpoints in the coding loci of ERG and
TMPRSS2, respectively, accompanied by interstitial deletion, or those
samples with microdeletions at the expected breakpoint sites in either or
both genes in conjunction with intergenic diploidy. This approach underesti-
mates the true frequency of TMPRSS2-ERG fusion by excluding tumors with
balanced rearrangement. Therefore, all other analyses described in this study
classified TMPRSS2-ERG status using the subset of cases with both aCGH
and expression data. Here, fusion-positive tumors were those having either
the genomic deletion described above or whole-transcript outlier expression
inferred from exon expression arrays as described above. We note that reclas-
sification of TMPRSS2-ERG status using individual exon expression adjacent
to the expected breakpoints in each coding sequence produced similar
results.
Pathway Analysis
The details of pathway curation and gene selection for the pathway diagrams
are described in the Supplemental Information. To determine pathway alter-
ation frequencies, we defined gene alterations by up- or downregulation
compared with normal prostate (outlier expression), or by somatic nonsynon-
ymous mutations. A given tumor was considered altered if at least one gene in
the pathway was altered. Mutations in genes known to be frequently deleted or
downregulated were considered as inactivating mutations (shades of blue in
the figures), while mutations in genes known to be frequently amplified or
upregulated were considered as activating mutations (shades of red). Addi-
tionally, the association of NCOA2 gain-of-function alteration (outlier overex-
pression or copy-number amplification) with androgen signaling was assessed
using a 29-gene signature of androgen stimulation (Hieronymus et al., 2006).
The significance of this association was tested in noncastrate primary tumors
by Student’s t test.
Hierarchical Clustering
Unsupervised hierarchical clustering of discretized copy-number alterations
(gain and loss, A0 and D0R 0.75; otherwise copy-neutral from RAE analysis)
assigned to regions of the unified breakpoint profile excluding known CNVs
was performed with the Manhattan distance measure and Ward’s linkage.
NCOA2 and AR Reporter Assay
For NCOA2 assays, pCDNA3-NCOA2 and PSA-Luc reporter were transfected
into LNCaP cells that were androgen-starved (20 hr) and then assayed for
growth after another 20 hr (One-Glo). Additional experimental details are avail-
able in the Supplemental Information.
Full methods are described in the Supplemental Information.20 Cancer Cell 18, 11–22, July 13, 2010 ª2010 Elsevier Inc.ACCESSION NUMBERS
Study data are deposited in NCBI GEO under accession number GSE21032.
The analyzed data can also be accessed and explored through the MSKCC
Prostate Cancer Genomics Data Portal at http://cbio.mskcc.org/prostate-
portal/.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, six tables, and Supplemental
Experimental Procedures and can be found online at doi:10.1016/j.ccr.2010.
05.026.
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